Prevalence of statin intolerance: a meta-analysis

European Heart Journal, Journal Year: 2022, Volume and Issue: 43(34), P. 3213 - 3223

Published: Jan. 11, 2022

Statin intolerance (SI) represents a significant public health problem for which precise estimates of prevalence are needed. remains an important clinical challenge, and it is associated with increased risk cardiovascular events. This meta-analysis the overall SI, according to different diagnostic criteria in disease settings, identifies possible factors/conditions that might increase SI.

Language: Английский

---

Predicting Cardiovascular Events in Familial Hypercholesterolemia

Circulation, Journal Year: 2017, Volume and Issue: 135(22), P. 2133 - 2144

Published: March 9, 2017

Background: Although risk factors for atherosclerotic cardiovascular disease (ASCVD) in familial hypercholesterolemia (FH) have been described, models predicting incident ASCVD not reported. Our aim was to use the SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study) define key patients with FH. Methods: is a multicenter, nationwide, long-term prospective cohort study of molecularly defined population FH or without previous ASCVD. Analyses and build prediction equation were developed, tested its ability discriminate who experience from those did over time. Results: We recruited 2404 adult followed up mean 5.5 years (SD, 3.2 years), during which 12 (0.5%) 122 (5.1%) suffered fatal nonfatal ASCVD, respectively. Age, male sex, history high blood pressure, increased body mass index, active smoking, low-density lipoprotein cholesterol lipoprotein(a) levels independent predictors Harrell C index 0.85 derived. The bootstrap resampling (100 randomized samples) original set internal validation showed degree overoptimism 0.003. Individual estimated each person an established diagnosis before enrollment by equation, modified Framingham American College Cardiology/American Heart Association Pooled Risk Equations. these 0.81, 0.78, 0.8, respectively, differences between other 2 significant ( P =0.023 =0.045). Conclusions: may be simple clinical predictors. This finding improve stratification could used guide therapy Clinical Trial Registration: URL: http://clinicaltrials.gov . Unique identifier: NCT02693548.

Language: Английский

---

Dyslipidemia and cardiovascular disease risk among the MASHAD study population

Lipids in Health and Disease, Journal Year: 2020, Volume and Issue: 19(1)

Published: March 16, 2020

Abstract Introduction Dyslipidemia may be defined as increased levels of serum total cholesterol (TC), low-density lipoprotein (LDL-C), triglycerides (TG), or a decreased high-density (HDL-C) concentration. is an established risk factor for cardiovascular disease (CVD). We aimed to investigate the association dyslipidemia and CVD events among population sample from Mashhad, in northeastern Iran. Material methods This prospective cohort study comprised 8698 men women aged 35–65 years who were recruited Mashhad Stroke Heart Atherosclerotic Disorder (MASHAD) study. Socioeconomic demographic status, anthropometric parameters, laboratory evaluations, lifestyle factors, medical history gathered through comprehensive questionnaire clinical assessment all participants. Cox regression model 95% confidence interval (CI) used evaluate its components with incidence. Results After 6 follow-up, 233 cases (including 119 unstable angina [US], 74 stable [SA], 40 myocardial infarction [MI]) identified population. Unadjusted baseline LDL-C, TC, TG positively associated entire (HR: 1.54, CI: 1.19–2; P -value< 0.01; HR: 1.53; 1.18–1.98; < 1.57; 1.27–2.03; 0.01, respectively). However, after adjusting confounding factors (age, body mass index [BMI], family CVD, smoking status [non-smoker, ex-smoker current smoker], lipid lowering drug treatment, anti-hypertensive hypertension, healthy eating [HEI], energy intake, presence diabetes mellitus), significant direct only remained between TC MI 2.71; 95%CI: 1.12–6.57; 0.05). Conclusion In present study, level was significantly men.

Language: Английский

---

Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study

European Heart Journal, Journal Year: 2021, Volume and Issue: 42(42), P. 4324 - 4332

Published: June 23, 2021

Emerging evidence suggests that remnant cholesterol (RC) promotes atherosclerotic cardiovascular disease (ASCVD). We aimed to estimate RC-related risk beyond low-density lipoprotein (LDL-C) and apolipoprotein B (apoB) in patients without known ASCVD.

Language: Английский

---

Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease

Nature Reviews Nephrology, Journal Year: 2017, Volume and Issue: 13(5), P. 297 - 310

Published: Feb. 20, 2017

Language: Английский

---